Barclays’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-25,400
| Closed | -$5.81M | – | 5513 |
|
|
2024
Q4 | $5.81M | Buy |
25,400
+1,300
| +5% | +$313K | ﹤0.01% | 2016 |
|
|
2024
Q3 | $5.88M | Sell |
24,100
-9,800
| -29% | -$2.19M | ﹤0.01% | 1954 |
|
|
2024
Q2 | $6.49M | Sell |
33,900
-25,900
| -43% | -$5.26M | ﹤0.01% | 1392 |
|
|
2024
Q1 | $11.8M | Buy |
59,800
+51,600
| +629% | +$9.46M | ﹤0.01% | 1274 |
|
|
2023
Q4 | $1.41M | Buy |
+8,200
| New | +$1.26M | ﹤0.01% | 3190 |
|
|
2020
Q2 | – | Sell |
-800
| Closed | -$118K | – | 6136 |
|
|
2020
Q1 | $118K | Hold |
800
| – | – | ﹤0.01% | 4683 |
|
|
2019
Q4 | $124K | Sell |
800
-1,600
| -67% | -$231K | ﹤0.01% | 5355 |
|
|
2019
Q3 | $324K | Sell |
2,400
-6,300
| -72% | -$825K | ﹤0.01% | 4606 |
|
|
2019
Q2 | $1.06M | Sell |
8,700
-3,200
| -27% | -$354K | ﹤0.01% | 3622 |
|
|
2019
Q1 | $1.24M | Buy |
11,900
+9,000
| +310% | +$929K | ﹤0.01% | 3166 |
|
|
2018
Q4 | $330K | Buy |
2,900
+1,900
| +190% | +$204K | ﹤0.01% | 4200 |
|
|
2018
Q3 | $115K | Sell |
1,000
-1,900
| -66% | -$208K | ﹤0.01% | 5429 |
|
|
2018
Q2 | $300K | Buy |
2,900
+1,800
| +164% | +$182K | ﹤0.01% | 4379 |
|
|
2018
Q1 | $108K | Sell |
1,100
-4,300
| -80% | -$406K | ﹤0.01% | 5329 |
|
|
2017
Q4 | $457K | Buy |
5,400
+3,300
| +157% | +$273K | ﹤0.01% | 3934 |
|
|
2017
Q3 | $162K | Sell |
2,100
-100
| -5% | -$7.65K | ﹤0.01% | 4601 |
|
|
2017
Q2 | $171K | Buy |
2,200
+1,300
| +144% | +$93K | ﹤0.01% | 4501 |
|
|
2017
Q1 | $65K | Buy |
900
+800
| +800% | +$55.3K | ﹤0.01% | 5180 |
|
|
2016
Q4 | $6K | Buy |
+100
| New | +$6.13K | ﹤0.01% | 6091 |
|
|
2016
Q3 | – | Sell |
-1,300
| Closed | -$82K | – | 6765 |
|
|
2016
Q2 | $82K | Buy |
1,300
+800
| +160% | +$47.2K | ﹤0.01% | 4536 |
|
|
2016
Q1 | $29K | Sell |
500
-45,700
| -99% | -$2.59M | ﹤0.01% | 5065 |
|
|
2015
Q4 | $2.45M | Buy |
46,200
+39,600
| +600% | +$2.23M | ﹤0.01% | 1861 |
|
|
2015
Q3 | $330K | Buy |
6,600
+4,300
| +187% | +$231K | ﹤0.01% | 3718 |
|
|
2015
Q2 | $129K | Sell |
2,300
-14,000
| -86% | -$884K | ﹤0.01% | 4466 |
|
|
2015
Q1 | $1.16M | Buy |
16,300
+10,300
| +172% | +$669K | ﹤0.01% | 2837 |
|
|
2014
Q4 | $336K | Sell |
6,000
-1,900
| -24% | -$99.2K | ﹤0.01% | 4224 |
|
|
2014
Q3 | $387K | Sell |
7,900
-16,000
| -67% | -$815K | ﹤0.01% | 4186 |
|
|
2014
Q2 | $1.2M | Buy |
23,900
+600
| +3% | +$29.7K | ﹤0.01% | 3157 |
|
|
2014
Q1 | $1.02M | Buy |
23,300
+10,200
| +78% | +$458K | ﹤0.01% | 3212 |
|
|
2013
Q4 | $616K | Sell |
13,100
-63,700
| -83% | -$3.22M | ﹤0.01% | 3888 |
|
|
2013
Q3 | $3.99M | Sell |
76,800
-124,100
| -62% | -$6.02M | ﹤0.01% | 1871 |
|
|
2013
Q2 | $9.07M | Buy |
+200,900
| New | +$9.53M | 0.01% | 1147 |
|
Other funds holding RMD
VCM
VPM
DAM
Barclays's RMD Position: Q1 2026 in Review
Barclays reduced its ResMed (RMD) stake by 7% in Q1 2026, selling an estimated $6.24M and leaving 334,114 shares worth $75M. The position accounts for 0.02% of the portfolio, ranked #593.
Barclays first reported a position in RMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q2 2025. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Barclays held 334,114 shares of ResMed worth $75M as of Q1 2026.
- Barclays sold 25,053 ResMed shares in Q1 2026, an estimated $6.24M.
- ResMed made up 0.02% of Barclays's portfolio in Q1 2026, its #593 holding.
- Barclays first reported a position in ResMed in Q2 2013 and has held it in 52 quarters since.
- Barclays's ResMed position peaked at $191M in Q2 2025.
- 939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.